Finance leadership for companies that need the function without the full-time hire. Steering and monthly reporting, cash and working capital, budgets and forecasts, relations with banks and investors — and the discipline that makes the numbers trustworthy when someone finally checks them.

Accounts, cash flows and commitments examined before anything is signed. Quality of earnings, working capital requirements, debt-like items and what sits off the balance sheet. What the numbers say, and what they leave out.

Asset-based, multiples and DCF approaches reconciled into a range that holds up. For a sale, a buy-out, a shareholder exit, a carve-out, or a disagreement where the figure has to survive scrutiny.

Financial and operational reorganisation when the trajectory has to change. Debt renegotiation, entity and scope structure, cost base and cash runway — and a plan that creditors and shareholders can both live with.

Known intimately by a few and not at all by the rest — which is the design, until growth is required. The margins are excellent, the scale is small on purpose, and the cash is already committed to lead times and stock. Every credible route to doubling runs through the thing that made the company work in the first place.

Two things decide the outcome: the product, and the scale behind it. A good formula earns its margin on the invoice and gives it back in listings, promotions, samples and returns, so volume without an orchestrated distribution is only a faster way to dilute the brand. Strength comes from choosing the channels, not from winning all of them.

A volume and distribution business, where the distance between a good year and a bad one is a matter of details. End margins are too thin to absorb an unplanned point of trade spend or a packaging revision, and much of the chain — brokers, distributors, retailer terms — is executed by people outside the company. Cost tracking is not reporting here; it is the operating discipline.

The group result is nothing more than the sum of its points of sale, less the cost of the centre. Each site has economics of its own, and a network figure will hide a location in difficulty for two quarters before anyone is obliged to act on it. The second risk is quieter: an administrative base that grows to the size of the network it was meant to serve.

There is no single lever. Margin is distributed across range, distribution, pricing and marketing, each of which can be improved on its own terms and at the expense of the others. Striking the balance between them is the actual work, and it cannot be done from a monthly summary — only from the detail underneath it.

Costs come first and returns come later, if they come at all. FDA approval sets the calendar, nothing can be sold before it is granted, and the date is never entirely in the company's hands — while development, quality and the regulatory file have to be run without error. Financing a wait of that length is a different discipline from financing a trading business.

Owning every stage of the chain guarantees nothing except that the margin is somewhere inside it. Each stage can show a result while the consolidated bottom line stays thin, and the honest questions are the uncomfortable ones: is each step genuinely better done in-house than bought outside, and does the transfer pricing policy measure performance or merely relocate it?